Long-acting bronchodilators improve Health Related Quality of Life in patients with COPD

详细信息    查看全文

• 作者：Fulvio Braido ; Ilaria Baiardini ; Mario Cazzola ; Guy Brusselle ; Fiorenza Marugo ; Giorgio Walter Canonica
• 关键词：Long-acting bronchodilators ; COPD ; Quality of life ; Health status
• 刊名：Respiratory Medicine
• 出版年：2013
• 出版时间：October, 2013
• 年：2013
• 卷：107
• 期：10
• 页码：1465-1480
• 全文大小：1302 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Summary

Background

Long-acting bronchodilators are first-line treatment for chronic obstructive pulmonary disease (COPD), and their efficacy on lung function and clinical parameters is recognized.

Objective

To explore the available evidence about the effects of long acting bronchodilators on Health Related Quality of Life (HRQoL) and Health Status (HS) in clinical research.

Methods

Randomized controlled trials published till December 2012 evaluating HRQoL/HS in COPD by means of validated questionnaires were analysed.

Results

Fifty-one trials on Long acting ¦Â₂ agonist (LABA) and Long acting Anticholinergic (LAMA) met the inclusion criteria. A total of 37,225 moderate-severe COPD patients testing 6 drugs, 12 different devices and 22 different dosages, with a study duration ranging from 4 weeks to 4 years were studied. A statistical significant HRQoL/HS improvement was reached in 93 % of the studies. Nevertheless, the Minimal Important Difference (MID) was reached in 70,6 % of the studies considering the difference between baseline and end of the study, and in 50 % when comparing active treatment and placebo.

Conclusions

The data coming from the review support the efficacy of long acting bronchodilators in improving HRQoL/HS of COPD patients. Further research evaluating HRQoL/HS as primary outcome and according to guidelines on Patient Reported Outcomes is needed.